2. Academic Validation
  3. The DDAH/ADMA/NOS pathway

The DDAH/ADMA/NOS pathway

  • Atheroscler Suppl. 2003 Dec;4(4):33-40. doi: 10.1016/s1567-5688(03)00032-1.
Cam T L Tran 1,  James M Leiper,  Patrick Vallance
Affiliations

Affiliation

  • 1 Centre for Clinical Pharmacology and Therapeutics, BHF Laboratories, Division of Medicine, University College London, 5 University Street, London, WC1E 6JJ, UK.
PMID: 14664901 DOI: 10.1016/s1567-5688(03)00032-1
Abstract

An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS), particularly asymmetric dimethylarginine (ADMA) regulate nitric oxide generation in numerous disease states. Two dimethylarginine dimethylaminohydrolase (DDAH) Enzymes metabolise ADMA. We and Others have postulated that activity of DDAH is a key determinant of ADMA levels in vivo. This review summarises recent advances in the regulation and function of DDAH Enzymes and its role in the regulation of nitric oxide generation.

Figures
Products